The CureSight system [Image courtesy of NovaSight]
Israeli startup NovaSight announced today that it has raised $8 million in a Series A round meant to support a large multi-center randomized pivotal study of its lazy eye treatment device.
Study results will support potential FDA 510(k) clearance for the device.
The money will also support development of future eye care products such as eye-tracking based active glasses for myopia control.
NovaSight’s CureSight system is an eye-tracking based lazy eye treatment that NovaSight officials think could replace traditional eye patching. CureSight provides cloud monitoring to caregivers and physicians while the child watches their content of choice from the comfort of home.
NovaSight’s other flagship product is the EyeSwift system, a comprehensive portable vision assessment device that the company says accurately and objectively screens for multiple vision impairments within seconds.
“During COVID-19 when alternative healthcare diagnosis and treatment methods are required, we’re putting emphasis on continuing to develop telehealth solutions. Our products are ideally positioned for remote diagnostics and home treatment,” NovaSight CEO Ran Yam said in a news release.
Rimonci Capital led the most recent funding round. The company previously raised $8 million, so it has now raised a total of $16 million.